A two-way pull has developed in drugs giant AstraZeneca, up 67p at 2603p, after its fat-busting drug Crestor was given approval by the US Food and Drug Administration this week. UBS has switched from neutral to buy and lifted its target price from 2850p to 3000p. But HSBC Securities is a seller of the Anglo-Swedish group, and WestLB Panmure and Lehman Brothers reckon the shares are overpriced. AZ is due to give a rundown of its business plan to brokers this evening.